Clinical Trial: Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.

U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550972) titled 'Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.' on April 19.

Brief Summary: A single-arm, single-center clinical trial evaluating efficacy (Phase #)

Study Start Date: May 01

Study Type: INTERVENTIONAL

Condition: Squamous Cell Carcinoma of the Head and Neck

Intervention: DRUG: A single-arm, single-center clinical trial evaluating efficacy

Combination therapy regimen: Pertuzumab combined with lenvatinib for neoadjuvant treatment Each 21-day period constitutes one treatment cycle, with pertuzumab administered at a dose of 3 mg/kg.(Up to 200 mg) Q3W, lenvatinib 8 mg QD.Total of 2-4 cycl...